Skip to main content

Table 2 Demographic and clinical characteristics between POPF (+) vs. POPF (-)

From: Safety and efficacy of pancreaticogastrostomy for hepatopancreatoduodenectomy compared to pancreaticojejunostomy for perihilar cholangiocarcinoma

 

POPF (+) (N=19)

POPF (-) (N=31)

P value

Patient backgrounds

   

 Age (years)

70 (58-79)

75 (50-82)

0.016

 Sex (female), n (%)

4 (21.1)

9 (29.0)

0.390

 Body mass index (kg/m2/)

21.3 (16.7-28.6)

20.8 (15.6-26.2)

0.803

Comorbidities

   

 Hypertension, n (%)

9 (47.4)

13 (41.9)

0.466

 Diabetes mellitus, n (%)

4 (21.1)

10 (32.2)

0.301

 Vascular disease*, n (%)

4 (21.1)

7 (22.6)

0.595

Charlson Risk Index

4 (2-6)

4 (1-7)

0.075

Serum albumin, (g/dL)

3.4 (2.4-4.3)

3.6 (2.4-4.3)

0.033

Serum CEA (ng/mL)

1.7 (0.6-5.6)

3.0 (0.6-5.4)

0.504

Serum CA19-9 (U/mL)

38 (9-3716)

49 (2-1386)

0.608

Type of cancer, n (%)

  

0.812

 Bile duct cancer

16 (84.2)

28 (90.3)

 

 Gallbladder cancer

2 (10.5)

2 (6.5)

 

 Intrahepatic cholangiocarcinoma

1 (5.3)

1 (3.2)

 

NAC or NACRT, n (%)

4 (21.1)

9 (29.0)

0.390

Preoperative biliary drainage, n (%)

16 (84.2)

28 (90.3)

0.324

ICG-15R (%), median (range)

12.0 (3.3-22.4)

9.1 (2.0-19.0)

0.992

PTPE, n (%)

18 (94.7)

23 (74.2)

0.068

Future remnant liver volume (%)

47.0 (36.5-69.0)

56.1 (33.7-82.0)

0.150

Remnant ICG-K, median (range)

0.073 (0.046-0.133)

0.080 (0.040-0.157)

0.330

Distance between HJ and PG/PJ (mm)

36.3 (16.3-69.0)

78.6 (16.9-121.8)

<0.001

Distance between the dissected artery and PG/PJ (mm)**

19.4 (5.1-33.5)

38.1 (8.0-72.1)

<0.001

Operative data

   

 Type of hepatectomy, L3/C2/L2/R2/R3

1/1/3/14/0

0/4/13/13/1

0.105

 Combined vascular resection, PV/HA/PV+HA

6/0/2

8/2/6

0.577

 Operation time (min)

675 (323-1375)

855 (348-1232)

0.181

 Blood loss (ml)

911 (255-1990)

472 (195-2368)

0.049

 Intraoperative RBC transfusion, n (%)

9 (47.4)

16 (51.6)

0.574

 Type of reconstruction (PG/PJ)

0/19

15/16

<0.001

Postoperative short-term outcomes

   

 Major morbidity (CD≧IIIa), n (%)

17 (89.5)

21 (67.7)

0.077

 postoperative massive ascites (ml)

1220 (385-3971)

990 (160-3513)

0.552

 postoperative massive ascites (≧1,500 ml/day)***

9 (47.4)

9 (29.0)

0.157

 Postoperative bile leakage, n (%)

1 (5.3)

5 (16.1)

0.249

 Post hepatectomy liver failure, n (%)

8 (42.1)

3 (9.7)

0.010

 Postoperative artery bleeding, n (%)

6 (31.6)

2 (6.5)

0.027

 Hospital stays (days)

59 (23-168)

40 (26-153)

0.089

 Postoperative 90-day mortality, n (%)

1 (5.3)

0 (0)

0.380

 In-hospital death, n (%)

2 (10.5)

1 (3.2)

0.320

Postoperative pathological data, n (%)

   

 Lymph node metastasis, n (%)

12 (63.2%)

21 (67.7)

0.487

 Resection margin, 0/1/2

14/4/1

21/10/0

0.217

  1. Data was presented as median values (minimum-maximum values)
  2. Abbreviations; CD, Clavien-Dindo. CHA, common hepatic artery. C2, central bisectionectomy. HA, hepatic artery. HJ, hepaticojejunostomy. L2, left hepatectomy. L3, left trisectionectomy. NAC, Neoadjuvant chemotherapy. NACRT, neoadjuvant chemoradiotherapy. PG, pancreaticogastrostomy. PJ, pancreaticojesunostomy. POPF, postoperative pancreatic fistula. PTPE, percutaneous transhepatic portal vein embolization. PV, portal vein. RBC, red blood cell. R2, right hepatectomy. R3, right trisectionectomy
  3. *Cardiovascular disease, cerebral vascular disease, etc
  4. **The distance between the PG/PJ anastomosis and the dissected artery closest to the PG/PJ anastomosis (e.g., common hepatic artery, gastroduodenal artery, proper hepatic artery, and left/right hepatic artery)
  5. ***Intraabdominal drain discharge more than 1,500mL/day during post operative 7 days
Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us